Shopping Cart
- Remove All
Your shopping cart is currently empty
Favezelimab (MK-4280), a humanized monoclonal antibody directed against LAG-3, inhibits the molecular interaction between LAG-3 and its ligand MHC class II, thereby restoring T-cell function. Favezelimab (MK-4280) has been evaluated as a candidate for colorectal cancer (CRC) research, particularly in studies that investigate synergistic effects in combination with the PD-L1 inhibitor Pembrolizumab (HY-P9902).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $332 | In Stock | |
| 5 mg | $996 | In Stock | |
| 10 mg | $1,690 | In Stock |
| Description | Favezelimab (MK-4280), a humanized monoclonal antibody directed against LAG-3, inhibits the molecular interaction between LAG-3 and its ligand MHC class II, thereby restoring T-cell function. Favezelimab (MK-4280) has been evaluated as a candidate for colorectal cancer (CRC) research, particularly in studies that investigate synergistic effects in combination with the PD-L1 inhibitor Pembrolizumab (HY-P9902). |
| Synonyms | MK-4280, MK4280 |
| Cas No. | 2231068-83-8 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.